References
- Friedberg J W, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 204–210
- Leoni L M, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309–317
- Knauf W U, Lissitchkov T, Aldaoud A, et al. Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: an updated analysis from an international phase III study. Blood 2008; 112: 728a
- Rai K R, Peterson B L, Appelbaum F R, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757
- Hallek M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy with fludarabine, cyclophosphamide, and rituximab versus fludarabine and cyclophosphamide improves response rates and progression-free survival of previously untreated patients with advanced chronic lymphocytic leukemia. Blood 2008; 112: 125 abstract
- Rummel M J, Chow K U, Hoelzer D, et al. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol 2002; 29: 12–14
- Robinson K S, Williams M E, van der Jagt R H, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473–4479
- Rummel M J, Al-Batran S E, Kim S Z, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin lymphoma. J Clin Oncol 2005; 23: 3383–3389
- Weide R, Mergenthaler U, Friesenhahn V, et al. Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 1468–1474
- Hamblin T J. Predicting progression–ZAP-70 in CLL. N Engl J Med 2004; 351: 856–857
- Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
- Rassenti L Z, Huynh L, Toy T L, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901
- Fischer K, Stilgenbauer S, Schweighofer C D, et al. Bendamustine in combination with rituximab for patients with relapsed chronic lymphocytic leukemia: a multicentre phase II trial of the German CLL study group. Blood 2008; 112: 128a